Drugs / ZV0203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05423977 | Dec 2021 → May 2023 overdue | — | Hangzhou Adcoris Biopharmacy Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZV0203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423977 ↗ |